Glyza 5 mg (Tablet)
Unit Price: ৳ 35.00 (3 x 10: ৳ 1,050.00)
Strip Price: ৳ 350.00
Medicine Details
Category | Details |
---|---|
Generic | Saxagliptin |
Company | Ibn sina pharmaceuticals ltd |
Also available as |
Indications
- Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Pharmacology
- Inhibits dipeptidyl peptidase IV (DPP-IV) enzyme resulting in prolonged active incretin levels
- Elevates the circulating levels of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) to stimulate insulin secretion in pancreatic beta-cells
- Reduces fasting and postprandial plasma glucose concentration in patients with type 2 diabetes mellitus
Dosage
- Recommended dosage of 2.5 mg or 5 mg once daily regardless of meals
- No dosage adjustment for patients with mild renal impairment (CrCl > 50 mL/min)
- Dosage of 2.5 mg once daily for patients with moderate or severe renal impairment, or with end-stage renal disease (ESRD) requiring hemodialysis (CrCl ≤ 50 mL/min)
- Dosage adjustment to 2.5 mg once daily when coadministered with strong CYP3A4/5 inhibitors
- Lower dose of insulin secretagogue or insulin may be required when used in combination with them
Administration
- May be taken with or without food
Interaction
- Increased risk of hypoglycemia with concomitant sulfonylureas; dose reduction may be necessary
- Increased serum levels with CYP3A4/5 inhibitors
- Concomitant CYP3A4 inducers may reduce the glycemic lowering effect
Contraindications
- Type 1 diabetes
- Diabetic ketoacidosis
Side Effects
- Pancreatitis
- Heart failure
- Hypoglycemia with concomitant use of sulfonylurea or insulin
- Hypersensitivity reactions
- Severe and disabling arthralgia
- Bullous pemphigoid
Pregnancy & Lactation
- Category B
Precautions & Warnings
- Moderate and severe renal impairment
- Pregnancy and lactation
Use in Special Populations
- No dosage adjustment needed for mild renal impairment
- Dosage of 2.5 mg once daily for moderate to severe renal impairment, including ESRD requiring hemodialysis
- No dosage adjustment needed for hepatic impairment
Therapeutic Class
- Dipeptidyl Peptidase-4 (DPP-4) inhibitor
Storage Conditions
- Store between 20-25°C